Pacritinib hydrochloride structure
|
Common Name | Pacritinib hydrochloride | ||
---|---|---|---|---|
CAS Number | 1228923-43-0 | Molecular Weight | N/A | |
Density | N/A | Boiling Point | N/A | |
Molecular Formula | C28H32N4O3.xClH | Melting Point | N/A | |
MSDS | N/A | Flash Point | N/A |
Use of Pacritinib hydrochloridePacritinib hydrochloride is a potent inhibitor of both wild-type JAK2 (IC50=23 nM) and JAK2V617F mutant (IC50=19 nM). Pacritinib hydrochloride also inhibits FLT3 (IC50=22 nM) and its mutant FLT3D835Y (IC50=6 nM). Pacritinib hydrochloride can be used for the research of acute myeloid leukemia (AML) and myelofibrosis (MF)[1][2][3]. |
Name | Pacritinib hydrochloride |
---|
Description | Pacritinib hydrochloride is a potent inhibitor of both wild-type JAK2 (IC50=23 nM) and JAK2V617F mutant (IC50=19 nM). Pacritinib hydrochloride also inhibits FLT3 (IC50=22 nM) and its mutant FLT3D835Y (IC50=6 nM). Pacritinib hydrochloride can be used for the research of acute myeloid leukemia (AML) and myelofibrosis (MF)[1][2][3]. |
---|---|
Related Catalog | |
Target |
JAK2V617F:19 nM (IC50) JAK3:520 nM (IC50) JAK1:1280 nM (IC50) JAK2wt:23 nM (IC50) Tyk2:50 nM (IC50) |
References |
Molecular Formula | C28H32N4O3.xClH |
---|